Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies
Author:
Funder
Amgen
Publisher
Elsevier BV
Subject
Biomedical Engineering,Bioengineering,Biotechnology
Reference51 articles.
1. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy;Raskov;Br J Cancer,2021
2. Discovery strategies to maximize the clinical potential of T-cell engaging antibodies for the treatment of solid tumors;Voynov;Antibodies,2020
3. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs;Haslam;JAMA Netw Open,2019
4. Bispecific T-cell engagers for cancer immunotherapy;Huehls;Immunol Cell Biol,2015
5. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab;Nagorsen;Expl Cell Res,2011
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Automated multicolumn screening workflow in ultra-high pressure hydrophilic interaction chromatography for streamlined method development of polar analytes;Journal of Chromatography A;2024-09
2. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia;Cellular and Molecular Life Sciences;2024-08-28
3. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31
4. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies;Frontiers in Immunology;2024-05-28
5. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3